The Increasing of Cell-Based Immunotherapy ProductsApplication in Cancers

The era of Regenerative Medicine as future medicine is uponus. Thousands of Ideas to market have demons trated profound,durable and potentially curative effects that are already improvinghuman quality of life for patients who have no otheravailable therapeutic options. Until ۲۰۲۱ products report in regenerativemedicine field included three main branches of genetherapy, cell therapy and tissue engineered based therapy. Butafter that time, cell-based immuno-oncology (IO) has emergedin categories independently. Gene therapy and cell-based IOdevelopers raised the vas t majority of inves tment, generating$۱۰.۲B and $۱۰.۱B in ۲۰۲۱, respectively. However, inves tmentin cell-based IO companies is growing at a fas ter pace than genetherapy financing. There is no reason except breakthrough treatmentfor cancer patients and their promising results. Accordingto the lates t reports, there are numerous clinical trials indifferent phases and achieved unprecedented bench to bedsideclinical success. So, related market authorized products are increasingsubsequently. There are six FDA approved CAR T celltherapy products. Also, there are a superiority in the number ofthis type of candidate products in the banner year of regulators’Regenerative Medicine Advanced Therapy (RMAT) designationsuch as FDA and EMA.